Table 3.
Multivariate analyses of prognostic factors of patients with CRCPM. Bold value indicates P < .05, HR hazard ratio, CI confidence interval, T stage of primary tumor, ascites, PCI score and Immunoscore were included in the Multivariate analysis 1; T stage of primary tumor, ascites, PCI score and TBM1 were included in the Multivariate analysis 2; T stage of primary tumor, ascites, PCI score and TBM2 were included in the Multivariate analysis 3
| OS | Multivariate analysis 1 | Multivariate analysis 2 | Multivariate analysis 3 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| T Stage | ||||||
| T4 vs T2-3 | 1.72 (0.72–4.10) | P = .219 | 2.09 0.86–5.07) | P = .103 | 2.07 (0.86–4.98) | P = .106 |
| Ascites | ||||||
| Yes vs no | 2.63 (1.28–5.40) | P = .009 | 1.96 (0.91–4.19) | P = .085 | 2.52 (1.21–5.25) | P = .014 |
| PCI | ||||||
| ≥10 vs <10 | 1.694 (0.81–3.56) | P = .163 | 1.91 (0.89–4.13) | P = .099 | 1.97 (0.92–4.22) | P = .079 |
| IS | ||||||
| High vs low | 0.35 (0.15–0.80) | P = .013 | ||||
| TBM1 | ||||||
| High vs low | 0.307 (0.14–0.67) | P = .003 | ||||
| TBM2 | ||||||
| High vs low | 0.29 (0.12–0.69) | P = .005 | ||||
| RFS | Multivariate analysis 1 | Multivariate analysis 2 | Multivariate analysis 3 | |||
| T Stage | ||||||
| T4 vs T2-3 | 2.13 (1.03–4.41) | P = .041 | 2.20 (1.06–4.55) | P = .034 | 2.30 (1.12–4.70) | P = .023 |
| Ascites | ||||||
| Yes vs no | 2.17 (1.17–4.01) | P = .014 | 2.19 (1.18–4.06) | P = .013 | 2.20 (1.18–4.08) | P = .013 |
| PCI | ||||||
| ≥10 vs <10 | 1.68 (0.91–3.08) | P = .095 | 1.78 (0.96–3.30) | P = .068 | 1.72 (0.93–3.19) | P = .085 |
| IS | ||||||
| High vs low | 0.69 (0.35–1.35) | P = .28 | ||||
| TBM1 | ||||||
| High vs low | 0.80 (0.40–1.58) | P = .521 | ||||
| TBM2 | ||||||
| High vs low | 0.93 (0.39–2.23) | P = .87 | ||||